Brown Brothers Harriman & Co. Has $70,000 Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Brown Brothers Harriman & Co. lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2,928.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212 shares of the medical research company’s stock after buying an additional 205 shares during the period. Brown Brothers Harriman & Co.’s holdings in Bio-Rad Laboratories were worth $70,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Bio-Rad Laboratories by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company’s stock worth $630,676,000 after acquiring an additional 12,168 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in Bio-Rad Laboratories during the fourth quarter worth $342,686,000. Sei Investments Co. grew its position in Bio-Rad Laboratories by 7.5% in the fourth quarter. Sei Investments Co. now owns 271,387 shares of the medical research company’s stock valued at $89,156,000 after purchasing an additional 18,873 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $83,681,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Bio-Rad Laboratories by 4.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 191,867 shares of the medical research company’s stock worth $63,030,000 after buying an additional 7,552 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BIO has been the topic of a number of recent research reports. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Price Performance

NYSE:BIO opened at $239.97 on Wednesday. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $235.84 and a 12-month high of $387.99. The stock’s 50 day moving average price is $289.28 and its two-hundred day moving average price is $321.35. The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of -3.69 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.